@article{a1f4bf23e5b24c339260011b2783b849,
title = "Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin",
abstract = "Background: Patient Reported Outcome (PRO) data comparing bolus (B-CP) with weekly (W-CP) cisplatin concurrent with radiation are lacking. Methods: We performed a retrospective study comparing PRO among 99 patients with head and neck radiation, 26% who received concurrent B-CP and 73% treated with W-CP. Results: W-CP patients had a higher Charlson comorbidity index (CCI) (P =.004). There were no differences in median cisplatin dose, PROs, percutaneous endoscopic gastrostomy (PEG) dependence or hospitalization between arms. Patients with a greater decline in their self-reported dysphagia score were more often PEG dependent at the end of radiation therapy (P =.03). There was also a trend toward PEG dependence with a higher maximum dysphagia score and greater change in aspiration score (P =.06). The maximum decline in white cell count and absolute neutrophil count were greater in the W-CP group (P =.04, P =.01). Conclusion: Both B-CP and W-CP are well tolerated. PROs do not suggest a benefit to W-CP.",
keywords = "bolus cisplatin, chemoradiation, head and neck cancer, patient reported outcome, weekly cisplatin",
author = "Mona Arbab and Chen, {Yu Hui} and Shana Criscitiello and Jason Glass and Fugazzotto, {Jo Ann} and Killoran, {Joseph H.} and Glenn Hanna and Jochen Lorch and Haddad, {Robert I.} and Margalit, {Danielle N.} and Tishler, {Roy B.} and Schoenfeld, {Jonathan D.}",
note = "Funding Information: Mona Arbab, Yu‐Hui Chen, Shana Criscitiello, Jason Glass, Jo Ann Fugazzotto, Joseph H. Killoran, and Danielle N. Margalit declare no conflict of interest. Glenn Hanna has received research support from BMS, NantKwest, Exicure, GSK, EMD Serono, Regeneron/Sanofi Genzyme and Kite, and is on the consulting boards for BMS, Merck, Regeneron/Sanofi Genzyme, and Maverick. Jochen Lorch has received research support for Novartis, Bayer, Millennium/Takeda and BMs, and is on the ad boards for Bayer, Genentech and Novartis. Robert I. Haddad has received research grant from Pfizer and is on the consulting board for MERCK, BMS, Genentech, Pfizer, Celgene, Eisai, and Astra Zeneca. Roy B. Tishler is on the Regeneron advisory board and PSI/Oragenics Data Safety Monitoring Board. Jonathan D. Schoenfeld reports Research support paid to the institution: Merck, BMS, Regeneron. Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",
year = "2020",
month = dec,
doi = "10.1002/hed.26432",
language = "English (US)",
volume = "42",
pages = "3670--3677",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "12",
}